Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

August 4, 2017

Study Completion Date

August 4, 2017

Conditions

EndocarditisBacteremia

Interventions

DRUG

Dalbavancin

Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.

DRUG

Standard of Care

Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.

Trial Locations (1)

Midway Immunology and Research Center, Ft. Pierce